AbbVie Reports P-IV (IMMpulse) Study Results of Skyrizi (risankizumab) for Adult Patients with Moderate Plaque Psoriasis
- The head-to-head P-IV study results published in British Journal of Dermatology evaluating Skyrizi vs Otezla in adult patients, showed that a higher proportion of patients achieved period A co-primary EPs of PASI 90 (55.9%) & sPGA 0/1 (75.4%) vs 5.1% & 18.4% with apremilast at 16wk.
- Patients achieved the 2EPs of PASI 75 at 16wk. was higher in risankizumab (84.7% vs 18.8%). At 52wk., patients re-randomized with risankizumab achieved period B 1EPs of PASI 90 (72.3% vs 2.6%) who failed to achieve PASI 75 after 16wks.
- Patients achieved the pre-specified EPs of PASI 90 (73.7%) & PASI 100 (63.6%) vs 4.5% & 2.7% after 52wks. & the safety profile was consistent with prior reported studies with no new safety signals. During periods A & B among the re-randomization arms, 6.8% & 5.2% discontinued treatment due to AEs
Ref: AbbVie | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.